Critical Analysis: Complete Genomics (GNOM) and Its Rivals

Complete Genomics (NASDAQ: GNOM) is one of 20 public companies in the “Medical Software & Technology Services” industry, but how does it contrast to its rivals? We will compare Complete Genomics to similar companies based on the strength of its earnings, institutional ownership, dividends, profitability, valuation, analyst recommendations and risk.

Insider & Institutional Ownership

62.7% of shares of all “Medical Software & Technology Services” companies are owned by institutional investors. 26.5% of shares of all “Medical Software & Technology Services” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Complete Genomics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Complete Genomics 0 0 0 0 N/A
Complete Genomics Competitors 91 443 842 13 2.56

As a group, “Medical Software & Technology Services” companies have a potential upside of 14.93%. Given Complete Genomics’ rivals higher possible upside, analysts plainly believe Complete Genomics has less favorable growth aspects than its rivals.

Profitability

This table compares Complete Genomics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Complete Genomics N/A N/A N/A
Complete Genomics Competitors -7.80% -6.73% 0.64%

Valuation and Earnings

This table compares Complete Genomics and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Complete Genomics N/A N/A -1.34
Complete Genomics Competitors $413.57 million -$24.55 million 416.63

Complete Genomics’ rivals have higher revenue, but lower earnings than Complete Genomics. Complete Genomics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Complete Genomics rivals beat Complete Genomics on 6 of the 8 factors compared.

About Complete Genomics

Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.

Receive News & Ratings for Complete Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Complete Genomics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply